Apr 14, 2024, 11:39
Nieves Martinez Lago: FDA approvals Tumor-Agnostic drugs
Nieves Martinez Lago, Medical Oncologist at University Hospital Complex of Ferrol, shared on X/Twitter:
“FDA approvals Tumor-Agnostic drugs:
- dMMR
- Pembrolizumab 2017
- Dostarlimab 2022
- MSI-H
- Pembrolizumab 2017
- TMB-High
- Pembrolizumab 2020
- NTRK fusions
- Larotrectinib 2018
- Entrectinib 2019
- BRAF V600E
- Dabrafenib + Trametinib 2022
- RET fusions
- Selpercatinib 2022
- HER2 3+
- T-derutxecan 2024.”
Source: Nieves Martinez Lago/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 12, 2024, 23:10
Nov 12, 2024, 23:07
Nov 12, 2024, 22:58
Nov 12, 2024, 22:56
Nov 12, 2024, 22:50
Nov 12, 2024, 22:46